JP2004511253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004511253A5 JP2004511253A5 JP2002536334A JP2002536334A JP2004511253A5 JP 2004511253 A5 JP2004511253 A5 JP 2004511253A5 JP 2002536334 A JP2002536334 A JP 2002536334A JP 2002536334 A JP2002536334 A JP 2002536334A JP 2004511253 A5 JP2004511253 A5 JP 2004511253A5
- Authority
- JP
- Japan
- Prior art keywords
- papp
- polypeptide
- seq
- amino acids
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 67
- 229920001184 polypeptide Polymers 0.000 description 65
- 102000004196 processed proteins & peptides Human genes 0.000 description 65
- 101000610209 Homo sapiens Pappalysin-2 Proteins 0.000 description 60
- 102100040154 Pappalysin-2 Human genes 0.000 description 59
- 238000000034 method Methods 0.000 description 49
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 26
- 239000012634 fragment Substances 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 21
- 108091033319 polynucleotide Proteins 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 239000002157 polynucleotide Substances 0.000 description 18
- 239000000758 substrate Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 102100035337 Bone marrow proteoglycan Human genes 0.000 description 12
- 101001095043 Homo sapiens Bone marrow proteoglycan Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108030001694 Pappalysin-1 Proteins 0.000 description 8
- 102000005819 Pregnancy-Associated Plasma Protein-A Human genes 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000012472 biological sample Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 5
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 201000010374 Down Syndrome Diseases 0.000 description 3
- 206010044688 Trisomy 21 Diseases 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108010052926 complement C3d,g Proteins 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 1
- 101000668170 Homo sapiens RNA-binding motif, single-stranded-interacting protein 2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 description 1
- 102100039690 RNA-binding motif, single-stranded-interacting protein 2 Human genes 0.000 description 1
- 101150105073 SCR1 gene Proteins 0.000 description 1
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000003450 affinity purification method Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24184000P | 2000-10-20 | 2000-10-20 | |
| DKPA200001571 | 2000-10-20 | ||
| PCT/DK2001/000695 WO2002032953A2 (en) | 2000-10-20 | 2001-10-19 | Pregnancy-associated plasma protein-a2 (papp-a2) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009291514A Division JP5072950B2 (ja) | 2000-10-20 | 2009-12-22 | 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004511253A JP2004511253A (ja) | 2004-04-15 |
| JP2004511253A5 true JP2004511253A5 (enExample) | 2007-07-05 |
| JP4460829B2 JP4460829B2 (ja) | 2010-05-12 |
Family
ID=44063430
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002536334A Expired - Fee Related JP4460829B2 (ja) | 2000-10-20 | 2001-10-19 | 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２） |
| JP2009291514A Expired - Fee Related JP5072950B2 (ja) | 2000-10-20 | 2009-12-22 | 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２） |
| JP2012147230A Pending JP2012229235A (ja) | 2000-10-20 | 2012-06-29 | 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２） |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009291514A Expired - Fee Related JP5072950B2 (ja) | 2000-10-20 | 2009-12-22 | 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２） |
| JP2012147230A Pending JP2012229235A (ja) | 2000-10-20 | 2012-06-29 | 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２） |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US7083940B2 (enExample) |
| EP (2) | EP2339020B1 (enExample) |
| JP (3) | JP4460829B2 (enExample) |
| AU (1) | AU2002210403A1 (enExample) |
| CA (2) | CA2818654A1 (enExample) |
| WO (1) | WO2002032953A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002210403A1 (en) * | 2000-10-20 | 2002-04-29 | Como Biotech Aps | Pregnancy-associated plasma protein-a2 (papp-a2) |
| AT500321B1 (de) * | 2003-12-30 | 2006-02-15 | Red Bull Gmbh | Verfahren zur diagnose des down-syndroms |
| CA2549066C (en) * | 2004-01-28 | 2012-11-13 | Turun Yliopisto | Diagnosing acute coronary syndrome by measuring levels of free papp-a |
| US20050277147A1 (en) * | 2004-06-11 | 2005-12-15 | Ameet Patki | Identifying chromosomal abnormalities in cells obtained from follicular fluid |
| US20060205651A1 (en) * | 2005-02-25 | 2006-09-14 | Royal College Of Surgeons In Ireland | Method of treating cancer |
| EP2161347B1 (en) * | 2005-03-18 | 2016-08-24 | The Chinese University Of Hong Kong | Markers for prenatal diagnosis and monitoring |
| US8653020B2 (en) * | 2008-01-25 | 2014-02-18 | Aarhus Universitet | Selective exosite inhibition of PAPP-A activity against IGFBP-4 |
| GB0910751D0 (en) | 2009-06-23 | 2009-08-05 | Procure Therapeutics Ltd | Prostate cancer vaccine |
| US9532404B2 (en) * | 2010-04-28 | 2016-12-27 | Watlow Electric Manufacturing Company | Flow through heater |
| WO2011144999A1 (en) * | 2010-05-17 | 2011-11-24 | Sandra Reznik | Plasma protein-a2 (papp-a2) as a marker for detecting risk of chromosomal abnormalities |
| CA2886489A1 (en) * | 2011-10-14 | 2013-04-18 | Aarhus Universitet | Diagnostic and prognostic use of prombp-complexes |
| US10670610B2 (en) | 2012-06-15 | 2020-06-02 | Wayne State University | Biomarker test for prediction or early detection of preeclampsia and/or HELLP syndrome |
| WO2014036440A2 (en) * | 2012-08-30 | 2014-03-06 | Ansh Labs Llc | Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10543259B2 (en) * | 2015-03-02 | 2020-01-28 | Children's Hospital Medical Center | Methods and compositions for the identification and treatment of individuals having or likely to develop short stature |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN110194801B (zh) * | 2018-02-26 | 2022-06-14 | 张灏 | 一种融合蛋白和多克隆抗体及其应用 |
| US11988674B2 (en) | 2018-08-07 | 2024-05-21 | University Of South Carolina | Methods for measuring gene expression levels to identify viable oocytes |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| TW202432584A (zh) * | 2022-11-15 | 2024-08-16 | 美商嘉來克生命科學有限責任公司 | 抗papp-a抗體及其使用方法 |
| TW202528331A (zh) * | 2023-11-13 | 2025-07-16 | 美商嘉來克生命科學有限責任公司 | 關於基於肽之ｐａｐｐ－ａ調節劑之組合物及方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI83662C (fi) * | 1980-07-17 | 1991-08-12 | Scripps Clinic Res | Diagnostik antikropp och foerfarande foer dess framstaellning. |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| GB9614615D0 (en) | 1996-07-11 | 1996-09-04 | Isis Innovation | Diagnosis of pre-eclampsia |
| US6432628B1 (en) * | 1997-08-26 | 2002-08-13 | Thomas Jefferson University | Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use |
| JP2002538804A (ja) * | 1999-03-15 | 2002-11-19 | オヴェルガルド，ミッチェル，トフト | インスリン様増殖因子結合タンパク質−４プロテアーゼ |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US6656700B2 (en) | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
| WO2001095855A2 (de) * | 2000-06-16 | 2001-12-20 | Harald Tschesche | Pregnancy-associated plasma-protein-e (papp-e) |
| AU2002210403A1 (en) | 2000-10-20 | 2002-04-29 | Como Biotech Aps | Pregnancy-associated plasma protein-a2 (papp-a2) |
| US6500630B2 (en) * | 2001-01-12 | 2002-12-31 | Mayo Foundation For Medical Education And Research | Marker for inflammatory conditions |
| EP1910569A4 (en) * | 2005-06-17 | 2009-08-05 | Genizon Biosciences Inc | GENEMAP GENE CARD OF HUMAN GENES ASSOCIATED WITH LONGEVITY |
| US20080071151A1 (en) * | 2006-06-30 | 2008-03-20 | Sogin David C | Method and Apparatus for Diagnosing Pre-eclampsia |
| ES2523220T3 (es) * | 2008-01-25 | 2014-11-24 | Perkinelmer Health Sciences, Inc. | Métodos para determinar el riesgo de complicaciones prenatales |
-
2001
- 2001-10-19 AU AU2002210403A patent/AU2002210403A1/en not_active Abandoned
- 2001-10-19 CA CA2818654A patent/CA2818654A1/en not_active Abandoned
- 2001-10-19 WO PCT/DK2001/000695 patent/WO2002032953A2/en not_active Ceased
- 2001-10-19 EP EP10183761.5A patent/EP2339020B1/en not_active Expired - Lifetime
- 2001-10-19 JP JP2002536334A patent/JP4460829B2/ja not_active Expired - Fee Related
- 2001-10-19 EP EP01978230.9A patent/EP1346061B1/en not_active Expired - Lifetime
- 2001-10-19 CA CA2464121A patent/CA2464121C/en not_active Expired - Lifetime
- 2001-10-22 US US09/983,025 patent/US7083940B2/en not_active Expired - Lifetime
-
2006
- 2006-06-13 US US11/451,495 patent/US20070141669A1/en not_active Abandoned
-
2009
- 2009-12-22 JP JP2009291514A patent/JP5072950B2/ja not_active Expired - Fee Related
-
2010
- 2010-10-28 US US12/914,312 patent/US20110091920A1/en not_active Abandoned
-
2012
- 2012-06-29 JP JP2012147230A patent/JP2012229235A/ja active Pending
- 2012-09-24 US US13/625,261 patent/US20130095482A1/en not_active Abandoned
- 2012-09-24 US US13/625,088 patent/US9005949B2/en not_active Expired - Fee Related
-
2014
- 2014-08-22 US US14/466,055 patent/US10392610B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004511253A5 (enExample) | ||
| JP2003527067A (ja) | Ａｃｒｐ３０（３０ｋｄの脂肪細胞補体関連タンパク質）の相同体ａｃｒｐ３０ｒ１ｌ | |
| JP2004511253A (ja) | 妊娠関連血漿蛋白−ａ２（ｐａｐｐ−ａ２） | |
| US20090214517A1 (en) | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease | |
| JP2000509967A (ja) | カルシウムチャンネルモジュレーターとして活性のあるアセチルコリンエステラーゼの可溶形態からのペプチド | |
| JPH10506015A (ja) | Ｇｌｕｔ−４小胞に由来するインスリン−依存性の膜アミノペプチターゼのクローニング | |
| JP2000083689A (ja) | シアロアドヘシンファミリ―メンバ――２（ｓａｆ―２） | |
| JP2004533825A5 (enExample) | ||
| EP0514481A1 (en) | Merosin, nucleic acids encoding, fragments and uses thereof | |
| JPH1118786A (ja) | 腫瘍壊死関連受容体ｔｒ７ | |
| JP2002300889A (ja) | クリングル関連クローン、ｈｔｈｂｚ４７ | |
| WO2005050198A2 (en) | Metadherin polypeptides, encoding nucleic acids and methods of use | |
| JP2002508934A (ja) | Ｔｎｆレセプターに対して相同性を有する、新規な核酸およびポリペプチド | |
| JPH11501817A (ja) | ヒト臍静脈内皮細胞で発現されるヒアルロン酸レセプタ | |
| JP2000125888A (ja) | シアロアドヘシンファミリ―メンバ――３ | |
| US6379951B1 (en) | Compounds for immunotherapy of breast cancer and methods for their use | |
| US6355430B1 (en) | Diagnostic and screening methods employing KIAA0101 | |
| JP2002186492A (ja) | ヒトｒｃｅ１ | |
| US6790622B2 (en) | Tumor suppressor encoding nucleic acid, PTX1, and methods of use thereof | |
| JP2002506437A (ja) | 癌の新規な検出および治療方法 | |
| AU2006200373B2 (en) | Novel tumor supressor encoding nucleic acid, PTX1, and methods of use thereof | |
| US20090018071A1 (en) | Epididymis-specific receptor protein | |
| WO2007050798A2 (en) | Lrrtm1 compositions and methods of their use for the diagnosis and treatment of cancer | |
| US20030022822A1 (en) | Novel compounds | |
| JPH10500841A (ja) | チロキシン結合タンパク質 |